Chronic Fibrosing Interstitial Lung Disease

Chronic fibrosing interstitial lung disease (ILD) refers to a group of conditions in which lung tissue gradually scars and stiffens. The scarring, known as fibrosis, reduces the lungs’ ability to transfer oxygen into the bloodstream. Over time, the damage accumulates and is generally irreversible, making early recognition important.

Medicine used to treat Chronic Fibrosing Interstitial Lung Disease

Ofev

Nintedanib

100mg

Developed to target idiopathic pulmonary fibrosis to alleviate breathing difficulties.

From $3.90 / capsule View

How progressive lung fibrosis develops and is managed

Most forms of fibrosing ILD share a common pattern: the immune system or an environmental trigger sets off repeated cycles of inflammation and repair that leave fibrous scar tissue behind. Common subtypes include idiopathic pulmonary fibrosis (IPF) and fibrosis occurring alongside autoimmune conditions such as rheumatoid arthritis or systemic sclerosis.

Persistent dry cough and exertional breathlessness that steadily worsens are the hallmark symptoms. A respiratory specialist typically confirms the diagnosis using high-resolution CT imaging and lung function testing.

Antifibrotic therapy aims to slow the rate of fibrosis rather than reverse existing damage. Nintedanib is one of the established antifibrotic agents used in this setting; it belongs to the broader field of respiratory health medicines targeting disease progression. Pulmonary rehabilitation, breathing exercises, and supplemental oxygen support quality of life alongside drug treatment.

Anyone experiencing progressive breathlessness or a new persistent cough that does not resolve should seek specialist respiratory assessment promptly.